中期<sup>18</sup>F-FDG-PET/CT在弥漫大B细胞淋巴瘤中的疗效评价方法及临床价值

李晓倩; 张利玲

doi:10.13201/j.issn.1004-2806.2018.11.019

中期¹⁸F-FDG-PET/CT在弥漫大B细胞淋巴瘤中的疗效评价方法及临床价值

李晓倩,
张利玲^,

- 华中科技大学同济医学院附属协和医院肿瘤中心(武汉, 430022)
基金项目:
国家自然科学基金(No:81672940)

华中科技大学自主创新基金(No:HUST 2014KXYQ019)

详细信息

通讯作者: 张利玲,E-mail:lily1228@sina.com

中图分类号: R733.4

收稿日期: 2017-10-09

¹⁸F-fluorodeoxyglucose positron emission tomography for interim response assessment of diffuse large B-cell lymphoma

More Information

Corresponding author: , E-mail: lily1228@sina.com

Received Date: 09 October 2017

摘要

- 中期PET /
- 弥漫大B细胞淋巴瘤 /
- 淋巴瘤 /
- 临床价值
Abstract: ¹⁸F-fluorodeoxyglucose positron emission tomography（PET）is acting as a major role for staging,assessment of remission and recurrence,and therapeutic evaluation in diffuse large B cell lymphoma.Nowadays,response-adapted or risk-adapted chemotherapy which depends on interim PET（I-PET）has being studied.For the positive I-PET,early alternative therapeutic approaches may improve outcome.However,the role of I-PET is in controversy.Since I-PET has a high negative predictive value but low positive predictive value,results of studies for I-PET have yielded mixed and confusing results.One of the major reasons is that the interpretation methods of IPET scan still need to be standardized,although the Deauville 5-point scale（5-PS）has been validated for use at the interim assessment.Here,we will review the assessment methods,including IHP,5-PS and semi-quantitative measurements,and the current status and clinical value of I-PET.
- interim PET /
- diffuse large B cell lymphoma /
- lymphoma /
- clinical value

HTML全文

参考文献(34)

[1]	周慧星,陈文明.18F-FDG PET/CT在多发性骨髓瘤疗效及预后评价的应用[J].临床血液学杂志,2018,31(3):227-231.
[2]	Bolshinsky M,Nabhan C.Interim PET scans in diffuse large B-cell lymphoma:is it ready for prime time?[J].Clin Lymphoma Myeloma Leuk,2016,16:655-661.
[3]	Han EJ,O JH,Yoon H,et al.FDG PET/CT response in diffuse large B-cell lymphoma:Reader variability and association with clinical outcome[J].Medicine,2016,96:e4983.
[4]	Gomez Leon N,Delgado-Bolton RC,Del Campo Del Val L,et al.Multicenter comparison of contrast-enhanced FDG PET/CT and 64-slice multi-detector-row CT for initial staging and response evaluation at the end of treatment in patients with lymphoma[J].Clin Nucl Med,2017,42:595-602.
[5]	Kanemasa Y,Shimoyama T,Sasaki Y,et al.Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients[J].Med Oncol,2017,34:29.
[6]	Fan Y,Zhang Y,Yang Z,et al.Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUVmax-liver-based interpretation for predicting the outcome in diffuse large B cell lymphoma[J].Leuk Lymphoma,2017,58:1-9.
[7]	de Oliveira Costa R,Hallack Neto A,Siqueira S,et al.Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era[J].Nucl Med Commun,2016,37:1095-1101.
[8]	Zhu D,Xu XL,Fang C,et al.Prognostic value of interim (18) F-FDG-PET in diffuse large B-cell lymphoma treated with rituximab-based immune-chemotherapy:a systematic review and meta-analysis[J].Int J Clin Exp Med,2015,8:15340-15350.
[9]	Horning SJ,Juweid ME,Schoder H,et al.Interim positron emission tomography scans in diffuse large B-cell lymphoma:an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study[J].Blood,2010,115:775-777.
[10]	Zhang Y,Fan Y,Ying Z,et al.Can the SUVmax-liver-based interpretation improve prognostic accuracy of interim and posttreatment ¹⁸F-FDG PET/CT in patient with diffuse large B-cell lymphoma?[J].Leuk Lymphoma,2017,3:1-10.
[11]	Le Gouill S,Casasnovas RO,et al.Interim PET-driven strategy in de novo diffuse large B-cell lymphoma:do we trust the driver?[J].Blood,2017,129:3059-3070.
[12]	Moskowitz CH,Schoder H,Teruya-Feldstein J,et al.Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma[J].J Clin Oncol,2010,28:1896-1903.
[13]	Mikhaeel NG.Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B-cell lymphoma:where are we now?[J].Leuk Lymphoma,2009,50:1931-1936.
[14]	Itti E,Meignan M,Berriolo-Riedinger A,et al.An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma:comparison between Deauville criteria and △SUVmax[J].Eur J Nucl Med Mol Imaging,2013,40:1312-1320.
[15]	Casasnovas RO,Meignan M,Berriolo-Riedinger A,et al.SUVmax reduction improve early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma[J].Blood,2011,118:37-43.
[16]	Mikhaeel NG,Smith D,Dunn JT,et al.Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL[J].Eur J Nucl Med Mol Imaging,2016,43:1209-1219.
[17]	Zhou MG,Chen YM,Huang HH,et al.Pognostic value of total lesion glycolysis of baseline ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma[J].Oncotaget,2016,7:83544-83553.
[18]	Cheson BD,Kostakoglu L.FDG-PET for early response assessment in lymphomas:Part 2-diffuse large B-cell lymphoma,use of quantitative PET evaluation[J].Oncology (Williston Park),2017,31:71-76.
[19]	Moskowitz CH.Interim PET-CT in the management of diffuse large B-cell lymphoma[J].Hematology Am Soc Hematol Educ Program,2012,2012:397-401.
[20]	黄洪辉,肖菲,韩晓凤,等.治疗中期¹⁸F-FDG PET/CT与初诊弥漫大B细淋巴瘤患者疗效及预后的相关性[J].肿瘤,2016,36(2):194-201.
[21]	Casasnova RO,Sasanelli M,Berriolo-Riedlinger A,et al.Baseline metabolic tumour volume is predictive of patient outcome in diffuse large B cell lymphoma[J].Blood,2012,120:1598-1599.
[22]	Song MK,Chung JS,Shin HJ,et al.Clinical significance of metabolic tumor volume by PET/CT in stageⅡ and Ⅲ of diffuse large B cell lymphoma without extranodal site involvement[J].Ann Hematol,2012,91:697-703.
[23]	Meignan M,Sasanelli M,Casasnovas RO,et al.Metabolic tumour volumes measured at staging in lymphoma:methodological evaluation on phantom experiments and patients[J].Eur J Nucl Med Mol Imaging,2014,41:1113-1122.
[24]	Malek E,Sendilnathan A,Yellu M,et al.Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods[J].Blood Cancer J,2015,5:e326.
[25]	Sasanelli M,Meignan M,Haioun C,et al.Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma[J].Eur J Nucl Med Mol Imaging,2014,41:2017-2022.
[26]	Casasnovas RO,Meignan M,Berriolo-Riedinger A,et al.Early interim PET scans in diffuse large B-cell lymphoma:Can there be consensus about standardized reporting,and can PET scans guide therapy choices?[J].Curr Hematol Malig Rep,2012,7:193-199.
[27]	Gallamini A,Hutchings M,Rigacci L,et al.Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:a report from a joint Italian-Danish study[J].J Clin Oncol,2007,25:3746-3752.
[28]	Johnson P,Federico M,Kirkwood A,et al.Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma[J].N Engl J Med,2016,374:2419-2429.
[29]	Kasamon YL,Wahl RL,Ziessman HA,et al.Risk-adapted therapy of aggressive lymphoma based on FDG-PET performed after 2 or 3 cycles of initial chemotherapy[J].Blood,2007,110:562A-562A.
[30]	Hertzberg M,Gandhi MK,Trotman J,et al.Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positiveinterim PET after 4 cycles of R-CHOP-14[J].Haematologica,2017,102:356-363.
[31]	Ladetto M,Buske C,Hutchings M,et al.ESMO consensus conference on malignant lymphoma:general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia[J].Ann Oncol,2016,27:2149-2160.
[32]	Pardal E,Coronado M,Martin A,et al.Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma:a phase II GELTAMO trial[J].Br J Haematol,2014,167:327-336.
[33]	Swinnen LJ,Li H,Quon A,et al.Response-adapted therapy for aggressive non-Hodgkin's lymphoma based in early[18F] FDG-PET scanning:ECOG-ACRIN Cancer Research Group study (E3404)[J].Br J Haematol,2016,170:56-65.
[34]	Stewart DA,kloiber R,Owen C,et al.Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma[J].Leuk Lymphoma,2014,55:2064-2070.